Sub 10% RoE for the past 3 years, and also in H1 FY 16. Higher provisioning norms has diluted the effect of higher operating leverage. Operating Income / Average Assets however has risen significantly - would this be due to higher growth of consumer durable financing?

Hi Rohit,

You can search about patent expiry for ANDAs on Orange book (for biologicals you have purple book which is available in pdf) which is their USFDA website. There you can type the molecule name and get data about the patent expiry.
I dont have much clarity about when the generic can be launched on exclusivity expiry or patent expiry. Actually, it varies from molecule to molecule. A drug can have various patent and exclusivity expiry dates. Even in exclusivity, there are various classifications like New Chemical Entity, Paediatric drug, Orphan Drug etc and an extension is given in case of any of these classifications (extension beyond the regular 5 years of exclusivity). Also, there can be some agreement which a generic player can enter with innovator eg Alembic has USFDA approval for gPristiq but hasnt launched it yet as per agreement with innovator because of various issues like litigations etc. I usually google about generic entry of a specific molecule. But still too difficult to predict.

Hi @ankitgupta

I am trying to understand exclusivity better. I tried to search a bit on USFDA site but didnt understand anything. You said above that the Exclusivity expires on Dec28, 2017 and Patent expires in in Dec 2019. So what happens in the period in between?

Is it so that no one can even file and ANDA for a drug that is under exclusivity?

Very good numbers from Indian Terrain
http://corporates.bseindia.com/xml-data/corpfiling/AttachLive/23A20535_5212_4705_934A_81D7915074D9_154029.pdf

One must note that last year festival season sales came in Q2. But this year festival season is in Q3. In that aspect result is very good.